John F. Bedard
Mr. John F. Bedard has been Senior Vice President of Worldwide Regulatory Affairs at Mannkind Corp. since October 2005. Mr. Bedard has been engaged as a principal in a pharmaceutical consulting practice since 2002. Prior to that, he served in senior management positions during a 15-year career at Bristol-Myers Squibb and served as Vice President of FDA Liaison and Global Strategy. He has 25 years of experience, successfully directing development and registration programs in various therapeutic areas, including cardiovascular, metabolic, dermatology, gastroenterology and immunology. He served as Vice President, FDA Liaison & Global Strategy at Bristol- Myers Squibb (BMS) for over ten years. During that time, he directed the regulatory activities for a number of medically important programs. Prior to BMS, he served as Group Director of Regulatory Affairs at Smith Kline & French Laboratories from 1985 to 1988. From 1981 to 1985, he served as Regulatory Associate then Assistant Director of Regulatory Affairs. He served as Group Director of Regulatory Affairs at Ayerst Laboratories. Mr. Bedard has extensive experience working with the FDA, including ten FDA Advisory Panels for significant pharmaceutical product approvals. He has been Director of Synvista Therapeutics, Inc. since September 2007. He served as Director of Epicept Corporation from January 4, 2006 to February 3, 2009. He served as Director of Maxim Pharmaceuticals Inc. since October 2004. He also served as Director of Smith Kline & French Laboratories. Mr. Bedard graduated from Rutgers University with a B.A. in Chemistry. He received his M.S. from Saint Joseph’s University.

Murray Lumpkin, M.D.
Dr. Lumpkin leads the Bill and Melinda Gates Foundation’s strategic initiatives around global regulatory systems, including working with partners such as the World Health Organization and other multinational organizations, regional regulatory harmonization/alignment initiatives, and national and regional medical products regulatory authorities. These initiatives are focused on making regulatory systems and processes more efficient and effective to help get medical products sooner to patients who need them in low- and middle-income countries, without sacrificing product quality and safety. Formerly he was deputy commissioner for International and Special Programs at the FDA.

Perry Nisen, M.D., Ph.D.
Dr. Nisen is CEO and Donald Bren Chief Executive Chair of the Sanford Burnham Prebys Medical Discovery Institute in La Jolla, California and Lake Nona, Florida. Previously, he was Senior Vice President, Science and Innovation at GlaxoSmithKline and held leadership roles as interim Chief Medical Officer, Senior Vice President and Head of Oncology Research and Development, and of Clinical Pharmacology and Discovery Medicine. In those roles he contributed to the successful discovery and development of multiple marketed products. He was a member of key governance, scientific advisory and investment Boards at GlaxoSmithKline. Formerly, he was the Lowe Foundation Professor of Neuro-oncology at the University of Texas Southwestern School of Medicine, then Vice President, Cancer Research at Abbott Laboratories.

Brandon Noble
Mr. Noble a licensed Agent of New York Life Insurance Company. Formerly he was a defensive tackle with the Washington Redskins and the Dallas Cowboys. He suffered career-encding methicillin-resistant Staphylococcus aureus (MRSA) infections. He was one of the first high-profile cases of MRSA in the NFL. He is an articulate spokesperson on antimicrobial resistance.

Cecil B. Pickett, Ph.D.
Dr. Pickett recently retires as President, Research and Development at Biogen Idec, Inc. Prior to joining Biogen Idec (2006 – 2009), Dr. Pickett held several senior R&D positions, including Corporate Senior Vice President of Schering-Plough Corp. and President of Schering-Plough Research Institute. Prior to joining Schering-Plough, he held several senior R&D positions at Merck & Co.

Dr. Pickett received his B.Sc. in biology from California State University at Hayward and his Ph.D. in cell biology from University of California at Los Angeles. He is a member of the Institute of Medicine of The National Academy of Sciences. Dr. Pickett previously served as a director of Biogen Idec. Board Committees: Compensation and Management Development Committee, Corporate Governance Committee and Science and Technology Committee (Chair).